Skip to main content

Table 4 Attrition rates by LOT

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

LOT

Frequency, N

Attrition, %

Deaths, n (%)

No subsequent treatment in follow-up, n (%)

Subsequent treatment, n (%)

Mean ± SD treatment duration, months (median)

Non-transplant

 1

22,062

2841 (12.9)

9716 (44.0)

9505 (43.1)

6.9 ± 9.6 (3.6)

 2

9505

56.9

1155 (12.2)

3168 (33.3)

5182 (54.5)

7.5 ± 9.5 (4.1)

 3

5182

45.5

636 (12.3)

1575 (30.3)

2971 (57.3)

6.5 ± 8.0 (3.7)

 4

2971

42.7

364 (12.3)

901 (30.3)

1706 (57.4)

5.7 ± 6.6 (3.4)

 5

1706

42.6

209 (12.3)

508 (29.8)

989 (58.0)

5.5 ± 6.4 (3.2)

Transplant

 1

2763

36 (1.3)

543 (19.6)

2184 (79.0)

6.3 ± 8.0 (4.2)

 2

2184

21.0

60 (2.7)

613 (28.1)

1511 (69.2)

6.1 ± 9.2 (2.7)

 3

1511

30.8

63 (4.2)

494 (32.7)

954 (63.1)

7.4 ± 9.8 (3.6)

 4

954

36.9

60 (6.3)

276 (28.9)

618 (64.8)

6.6 ± 9.4 (3.4)

 5

618

35.2

49 (7.9)

180 (29.1)

389 (62.9)

5.6 ± 6.2 (3.3)

  1. LOT Line of therapy, SD Standard deviation